Uncategorized Archives - Page 21 of 251

TuesdayJul 11, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023 The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations Lexaria looks to build on the momentum gathered so far, and its management is…

WednesdayJul 05, 2023 9:00 am

The 2023 Alternative Products Expo, Dallas Chapter – “Everything Counterculture Under One Roof”

ZJ Events is proud to announce the third leg of its four-part Alternative Products Expo – the Dallas Chapter – that will be held at the Kay Bailey Hutchison Convention Center Dallas. The expo, which promises to be the ultimate event for anyone in the counterculture industry, will serve as a melting pot for everything counterculture, with featured products including CBD, mushrooms, nicotine replacement, dietary supplements, and nootropics, among others. The event will be held from July 13-15, bringing together hundreds of leading brands such as 3Chi, Mellow Fellow, and Cali Kulture. The event will also offer a platform where…

WednesdayJul 05, 2023 4:20 am

420 with CNW — Cannabis High Linked to Improved Symptoms Among Patients Using Medical Marijuana

More than 30 states now allow their residents to purchase and even grow medical cannabis to treat several allowed conditions. Even though cannabis users typically tend to be younger, a decent portion of medical marijuana patients are older people dealing with conditions such as insomnia and chronic pain from arthritis. For a lot of medical marijuana patients, especially older ones, the “high” that comes with consuming THC cannabis isn’t always welcome. Some patients have taken to using cannabis alongside CBD (cannabidiol) to reduce the high, while some researchers have even developed a cannabis strain that delivers the benefits without the…

FridayJun 30, 2023 2:48 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Published Peer-Reviewed Article on DehydraTECH(TM)-CBD, Bringing Publication Total to Eight

Lexaria’s latest peer-reviewed publications were published in June 2023 in the International Journal of Molecular Sciences, Advances in Therapy, and Biomedicine & Pharmacotherapy Lexaria’s eight peer-reviewed publications support the company’s pursuit of launching an FDA-registered IND program to formally investigate DehydraTECH(TM)-CBD for hypertension The global cardiovascular drug market was worth $146.5 billion and is expected to reach $173.5 billion in 2026 – making patent protection crucial in commercial markets To date, Lexaria has a robust intellectual property portfolio with 34 patents granted and many more pending worldwide Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced…

WednesdayJun 28, 2023 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Robust Intellectual Property Portfolio to 34 Worldwide Patents with Receipt of 4 New Granted in Canada, US

Lexaria Bioscience recently received four new patents granted in Canada and the United States In the U.S., the company received two new hypertension-related patents expected to be of particular importance as the company pursues FDA approval for a Phase 1b study evaluating DehydraTECH(TM)-processed CBD So far, the company has a robust intellectual property portfolio comprising 34 patents granted worldwide The strong portfolio gives the company the necessary impetus and peace of mind to pursue multiple large markets, starting with the multi-billion dollar cardiovascular drugs market The company has conducted five human clinical studies that have provided insights into the potential…

MondayJun 26, 2023 12:00 pm

2023 Maine Cannabis Convention Joins MMCM’s HomeGrown TradeShow for Nation-leading Event

The Maine Cannabis Convention, billed as the largest B2B event in the state, will move from Portland to Augusta this year for its seventh annual gathering in a state where sales of recreational cannabis nearly doubled last year. Since the Maine adult-use market’s first full month of operation in October 2020, the state’s industry saw new records set every month through August 2022, and by year-end the sales figures were still close to that peak (https://cnw.fm/vIKfh). The 2023 Maine Cannabis Convention take place August 12-13th and will continue the series’ tradition of bringing together the region's best speakers on multiple…

ThursdayJun 22, 2023 4:20 pm

420 with CNW — How to Leverage Consumer Data While Marketing Cannabis

The cannabis industry exists in a precarious position. While dozens of states have legal and robust cannabis markets, the federal government still classifies cannabis as a controlled drug. This federal classification places significant restrictions on America’s state-legal cannabis industry, with cannabis marketing being the hardest hit. Cannabis businesses in most states have to contend with strict marketing limitations and can’t use most conventional advertising avenues such as social media to market their products. Despite these barriers, businesses in the cannabis space can still optimize their marketing efforts by leveraging consumer data. Studying how different kinds of consumers approach cannabis use…

ThursdayJun 22, 2023 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Findings in Diabetes Animal Study and Two Other R&D Programs

Diabetes – Blood glucose levels reduced by 19.9% with patented DehydraTECH(TM) processed CBD Epilepsy – Lower dosages of DehydraTECH-CBD were needed to achieve the same results of Epidiolex(R) in the company’s animal epilepsy study Dementia – Lexaria determined that a longer testing duration is needed for DehydraTECH-CBD in cognition studies Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, including the company’s patented DehydraTECH(TM) technology, recently reported additional findings from its diabetes animal study DIAB-A22-1, as well as updates on two other applied R&D programs for dementia (DEM-A22-1) and epilepsy (EPIL-A21-1). In March, Lexaria announced that it had…

ThursdayJun 15, 2023 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) May Announcements Show Resolve to Continue Supporting R&D ‘Lifeblood’

In May, Lexaria made a number of positive announcements related to its R&D initiatives In addition to holding its 2023 Annual Meeting, the company completed dosing for its human clinical nicotine study, NIC-H22-1 Lexaria also reported 900% improvements in delivery of DehydraTECH(TM) processed estrogen into blood plasma in an animal study In a human hypertension study, the company announced that its DehydraTECH-CBD formulation resulted in significant reductions in the blood plasma levels of pro-inflammatory biomarkers (IL 8, 10, and 18) These biomarkers are linked to cardiovascular disease (“CVD”) and many other conditions, such as asthma, lung diseases, chronic kidney disease,…

WednesdayJun 14, 2023 4:20 pm

420 with CNW — Bruen Ruling Could Bring Good Tidings to Marijuana Movement

A 2022 ruling by the Supreme Court has radically changed a century-old U.S. gun law and significantly altered how courts assess gun laws. Judges in the New York Rifle and Pistol Association v. Bruen overturned a 100-year-old gun safety law and ruled that a New York law requiring licenses to conceal carry weapons in public was unconstitutional. The overturned New York gun law was strikingly similar to gun safety laws in seven other states, and the June 2022 ruling set a precedent for overturning these laws. In the aftermath of the Supreme Court ruling, judges in several states overturned gun…